The US drug regulator approved a daily pill version of Novo Nordisk’s Wegovy injection, giving the Danish drugmaker a head start as the first to market in the next big competitive frontier in ...

Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.

Moderately bullish activity in Pfizer (PFE), with shares up 4c, or 0.14%, near $25.23. Options volume relatively light with 116k contracts traded ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

New Jersey-based pharma companies joined White House drug pricing deals aimed at lowering prescription drug costs under Trump’s policy.

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.” ...

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

AI - or was it? Judging by customer use cases, the answer is: not yet. But that doesn't mean customers aren't pursuing AI aggressively. From AI readiness to robotics progress, here's what we learned ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

Pfizer Inc. (NYSE:PFE) creates and sells medicines and vaccines for several health conditions, including heart disease, ...